Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pharvaris N.V. (NQ: PHVS )

18.60 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 18.60
Bid (Size) 7.440 (2)
Ask (Size) 24.24 (1)
Prev. Close 18.60
Today's Range 18.60 - 18.60
52wk Range 15.00 - 33.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense
Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine. 
Via Investor's Business Daily
Pharvaris Announces Annual Meeting of Shareholders
From Pharvaris N.V.
Via GlobeNewswire

Performance

YTD
-28.10%
-28.10%
1 Month
+2.37%
+2.37%
3 Month
-10.88%
-10.88%
6 Month
-35.86%
-35.86%
1 Year
+14.39%
+14.39%

More News

Read More
Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
From Pharvaris N.V.
Via GlobeNewswire
Analyst Expectations for Pharvaris's Future
Via Benzinga
Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses
From Pharvaris N.V.
Via GlobeNewswire
PHVS Stock Earnings: Pharvaris Misses EPS for Q1 2024
Via InvestorPlace
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
PHVS Stock Earnings: Pharvaris Misses EPS for Q4 2023
Via InvestorPlace
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
From Pharvaris N.V.
Via GlobeNewswire
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Announces Extraordinary Meeting of Shareholders
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris to Present at the WSAAI Annual Meeting 2024
From Pharvaris N.V.
Via GlobeNewswire
Top-Notch Pharvaris Eyes Profit-Taking Zone On A Key FDA Decision
Via Investor's Business Daily
Exposures Product Safety
FDA Clears Pharvaris' Trial For Investigational Drug For Swollen Blood Vessels, Stock Jumps
Via Benzinga
Exposures Product Safety
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023
From Pharvaris N.V.
Via GlobeNewswire
Gold Moves Higher; Campbell Soup Earnings Top Expectations
Via Benzinga
Topics Stocks
Exposures US Equities
Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Turnaround For Pharvaris Since FDA Clinical Hold - Data Shows Its Oral Hereditary Angioedema Treatment Cuts Attacks
Via Benzinga
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.